This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cazzaniga, G. Articles by Biondi, A. Search for Related Content PubMed PubMed Citation Articles by Cazzaniga, G. Articles by Biondi, A.

The Paired Box Domain Gene PAX5 Is Fused to ETV6/TEL in an Acute Lymphoblastic Leukemia Case

Clinica Pediatrica, Università di Milano-Bicocca, Ospedale San Gerardo, 20052 Monza, Italy [G. C., M. D., G. G., A. A., A. B.]; MRC Molecular Haematology Unit, Institute of Molecular Medicine, Oxford, OX3 9DU United Kingdom [S. T., L. K.]; and Divisione di Ematologia, Ospedale San Gerardo, 20052 Monza, Italy [E. P.]

The PAX5 gene, encoding the B-cell-specific activator protein, is a critical determinant of commitment to the B-lymphocyte pathway. This gene, mapped at 9p13, is juxtaposed to the immunoglobulin heavy chain (IgH) gene as a result of the t(9;14)(p13;q32), a rare but recurring translocation found in a subset of B-cell non-Hodgkin’s lymphoma cases. In all of these, this translocation results in deregulated expression of the gene product because of the proximity of IgH. We present here the molecular characterization of a previously reported acute lymphoblastic leukemia case carrying a t(9;12)(q11;p13) translocation. Using 5' rapid amplification of cDNA ends PCR, a novel chimeric transcript was identified that contained the NH₂-terminal region of PAX5 and most of the ETV6/TEL gene on 12p13. According to the fusion transcript, the resulting chimeric protein would retain the PAX5 paired-box domain and both the helix-loop-helix and DNA binding domains of TEL. Thus, it is reasonable to hypothesize that this protein could act as an aberrant transcription factor. This is the first report of PAX5 rearrangement in a human malignancy resulting in a chimeric transcript.

This article has been cited by other articles:

				N. Kawamata, S. Ogawa, M. Zimmermann, B. Niebuhr, C. Stocking, M. Sanada, K. Hemminki, G. Yamatomo, Y. Nannya, R. Koehler, et al. Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray PNAS, August 19, 2008; 105(33): 11921 - 11926. [Abstract] [Full Text] [PDF]

				G. Fazio, C. Palmi, A. Rolink, A. Biondi, and G. Cazzaniga PAX5/TEL Acts as a Transcriptional Repressor Causing Down-modulation of CD19, Enhances Migration to CXCL12, and Confers Survival Advantage in pre-BI Cells Cancer Res., January 1, 2008; 68(1): 181 - 189. [Abstract] [Full Text] [PDF]

				M. Bousquet, C. Broccardo, C. Quelen, F. Meggetto, E. Kuhlein, G. Delsol, N. Dastugue, and P. Brousset A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5 Blood, April 15, 2007; 109(8): 3417 - 3423. [Abstract] [Full Text] [PDF]

				F. Nakamura, Y. Nakamura, K. Maki, Y. Sato, and K. Mitani Cloning and Characterization of the Novel Chimeric Gene TEL/PTPRR in Acute Myelogenous Leukemia with inv(12)(p13q13) Cancer Res., August 1, 2005; 65(15): 6612 - 6621. [Abstract] [Full Text] [PDF]

				E. Tiacci, S. Pileri, A. Orleth, R. Pacini, A. Tabarrini, F. Frenguelli, A. Liso, D. Diverio, F. Lo-Coco, and B. Falini PAX5 Expression in Acute Leukemias: Higher B-Lineage Specificity Than CD79a and Selective Association with t(8;21)-Acute Myelogenous Leukemia Cancer Res., October 15, 2004; 64(20): 7399 - 7404. [Abstract] [Full Text] [PDF]